Rezafungin

Routes of
administrationIntravenousDrug classAntifungalATC codeLegal statusLegal status Pharmacokinetic dataExcretionFecesIdentifiersCAS NumberPubChem CIDDrugBankUNIIKEGGChEBIChemical and physical dataFormulaC₆₃H₈₅N₈O₁₇⁺Molar mass1226.412 g·mol⁻¹

Rezafungin, sold under the brand name Rezzayo, is a medication used for the treatment of invasive candidiasis.^[2] It is an echinocandin antifungal.^[1][4]

Rezafungin was approved for medical use in the United States in March 2023,^[1][5][6] and in the European Union in December 2023.^[2][3]

Medical uses

In the United States, rezafungin is indicated indicated in adults who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.^[1]

In the European Union, rezafungin is indicated for the treatment of invasive candidiasis in adults.^[2]

Society and culture

Legal status

Rezafungin was approved for medical use in the United States in March 2023,^[1][7][8] The FDA granted the application for rezafungin orphan drug, fast track, and priority review designations.^[9]

In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rezzayo, intended for the treatment of invasive candidiasis in adults.^[2] The applicant for this medicinal product is Mundipharma GmbH.^[2] Rezafungin was approved for medical use in the European Union in December 2023.^[3]

Brand names

Rezafungin is the international nonproprietary name.^[10]

Rezafungin is sold under the brand name Rezzayo.^[2]

References

External links

• "Rezafungin Injection". U.S. Food and Drug Administration. 18 April 2023.